APGE

NEUTRALM&A

Apogee Therapeutics, Inc.

2026-08-25

Price

$134.85

+0.04%

This is the 2026-08-25 snapshot — the signals and analysis for APGE as of this single trading day.

View full APGE research hub →

Score11.0Top Tier

Signals6/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.5xvs 20d avg

Analysis

Apogee Therapeutics (APGE) is exhibiting textbook merger arbitrage price action following AbbVie's definitive agreement to acquire the company for $135.11 per share in cash. The technical signals—QUIET_STORM, STEADY_CLIMB, and PERFECT_STACK—combined with an exceptionally low 1.6% annualized volatility, perfectly reflect a stock pinned tightly to its deal price as institutional capital absorbs the remaining spread. Furthermore, the prevailing RISK_ON macro regime and highly accommodative credit environment provide high conviction that the $10.9 billion acquisition will close smoothly in Q3 2026 without systemic or financing disruptions.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKSELLER FATIGUE

Key Takeaways

M&A Arb Pin: APGE is trading at $134.85, representing a highly compressed arbitrage spread against AbbVie's $135.11 all-cash acquisition offer.
Technical Confirmation: Ultra-low volatility (1.6% annualized) and muted volume (0.5x 20-day average) confirm institutional wait-and-see behavior typical of pending acquisitions.
Risk Factor: The only structural risk remaining is regulatory intervention (FTC/antitrust) or a failure to secure shareholder approval before the expected Q3 2026 close.

← Back to 2026-08-25 View Full APGE History →Yahoo Finance &nearr;